Drug intelligence / Profile preview

EP-9001A

Development stage: Phase 1
Lead developer: Chengdu Youluo Biotechnology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

EP-9001A is a humanized monoclonal antibody that targets nerve growth factor (NGF). By inhibiting NGF, EP-9001A is designed to alleviate neuropathic pain, including cancer pain, through blockade of the NGF signaling pathway. The drug is being developed as an injectable biologic and has undergone Phase 1/2 clinical trials to assess its safety, tolerability, pharmacokinetics, and immunogenicity in healthy volunteers. EP-9001A represents a novel mechanism of action for pain management therapies and was initially developed by Chengdu Youluo Biotechnology and further advanced by Chengdu Easton Biopharmaceuticals[1][3][4].

Targets

NGF (Nerve growth factor)

Beyond the preview

Go deeper on EP-9001A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EP-9001A.

Explore the full profile